Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Passes Above 50-Day Moving Average – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $34.08 and traded as high as $37.11. Collegium Pharmaceutical shares last traded at $36.59, with a volume of 1,618,493 shares.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Collegium Pharmaceutical Trading Up 5.0%

The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 17.94 and a beta of 0.74. The business has a fifty day moving average of $34.08 and a two-hundred day moving average of $39.67. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.49 earnings per share. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd increased its position in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $61,000. PNC Financial Services Group Inc. raised its stake in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.